In mouse models of PTEN-null prostate cancer and PTEN-treated melanoma, the administration of mPTEN@NP, a novel polymeric nanoparticle platform designed for PTEN mRNA delivery, resulted in the reduction of the immunosuppressive microenvironment within the tumor tissue. Here, PTEN is linked to prostate carcinoma.